Physician profile
Raul Rivera
NPI 1205853843
$8,184.18
in general payments reported to CMS, 2019-2025
42 companies · $666 in 2025
The $666 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $1,355 · 2021: $1,263 · 2022: $1,409 · 2023: $1,015 · 2024: $752 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,470.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,093.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $929.46 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $709.52 | 2021-2025 | |
| Lilly USA, LLC | $475.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $464.09 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $316.64 | 2020-2023 | |
| Allergan, INC. | $311.37 | 2019-2020 | |
| Amgen INC. | $290.47 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $214.02 | 2021-2023 | Linzess, Viberzi |
| Amarin Pharma, INC. | $207.42 | 2019-2020 | |
| Exact Sciences Corporation | $188.25 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $145.19 | 2023-2024 | Rexulti |
| Valeritas, INC. | $131.84 | 2019 | |
| Pfizer INC. | $130.78 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.